Terminal glycosylation and disease: influence on cancer and cystic fibrosis

Terminal glycosylation has been a recurring theme of the laboratory. In cystic fibrosis (CF), decreased sialic acid and increased fucosyl residues in alpha1,3 position to antennary N-acetyl glucosamine is the CF glycosylation phenotype. The glycosylation phenotype is reversed by transfection of CF a...

Full description

Saved in:
Bibliographic Details
Published in:Glycoconjugate journal 2000-07, Vol.17 (7-9), p.617-626
Main Authors: Scanlin, T F, Glick, M C
Format: Article
Language:English
Subjects:
Animals
Carbohydrate Sequence
Cystic fibrosis
Cystic Fibrosis - genetics
Cystic Fibrosis - history
Cystic Fibrosis - metabolism
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Cystic Fibrosis Transmembrane Conductance Regulator - history
Cystic Fibrosis Transmembrane Conductance Regulator - metabolism
Genetic Therapy
Glycosylation
History, 20th Century
Humans
Membrane Glycoproteins - chemistry
Membrane Glycoproteins - metabolism
Molecular Sequence Data
N-Acetylneuraminic Acid - chemistry
N-Acetylneuraminic Acid - history
N-Acetylneuraminic Acid - metabolism
Neoplasms - history
Neoplasms - metabolism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Terminal glycosylation has been a recurring theme of the laboratory. In cystic fibrosis (CF), decreased sialic acid and increased fucosyl residues in alpha1,3 position to antennary N-acetyl glucosamine is the CF glycosylation phenotype. The glycosylation phenotype is reversed by transfection of CF airway cells with wtCFTR. In neuronal cells, polymers of alpha2,8sialyl residues are prominent in oligodendrocytes and human neuroblastoma. These findings are discussed in relationship to early studies in our laboratories and those of other investigators. The potential extension of these concepts to future clinical therapeutics is presented.
ISSN:0282-0080
1573-4986
DOI:10.1023/a:1011034912226